X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40) 40
humans (39) 39
oncology (26) 26
adoptive immunotherapy (19) 19
cancer (19) 19
immunotherapy (18) 18
female (17) 17
animals (16) 16
male (13) 13
medicine, research & experimental (13) 13
biotechnology & applied microbiology (12) 12
cik cells (12) 12
immunology (12) 12
solid tumors (12) 12
neoplasms - therapy (10) 10
aged (9) 9
antitumor-activity (9) 9
melanoma (9) 9
middle aged (9) 9
acute myeloid-leukemia (8) 8
cytokine-induced killer cells - immunology (8) 8
immunotherapy, adoptive (8) 8
immunotherapy, adoptive - methods (8) 8
mice (8) 8
research (8) 8
tumors (8) 8
adult (7) 7
cd8 t-cells (7) 7
cytokine-induced killer cells - transplantation (7) 7
lymphocytes (7) 7
neoplasms - immunology (7) 7
osteosarcoma (7) 7
phase-i (7) 7
review (7) 7
treatment outcome (7) 7
antitumor activity (6) 6
bone-marrow-transplantation (6) 6
cell line, tumor (6) 6
chemotherapy (6) 6
melanoma - immunology (6) 6
melanoma - therapy (6) 6
t-cells (6) 6
therapy (6) 6
transplantation (6) 6
antigens, neoplasm - immunology (5) 5
clinical trials as topic (5) 5
cytotoxicity, immunologic (5) 5
expression (5) 5
hematology (5) 5
hematopoietic stem cells (5) 5
in-vivo (5) 5
induced killer-cells (5) 5
stem cells (5) 5
angiogenesis (4) 4
animal models (4) 4
anticancer properties (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
apoptosis (4) 4
care and treatment (4) 4
cells, cultured (4) 4
cik (4) 4
flow cytometry (4) 4
hematology, oncology and palliative medicine (4) 4
hematopoietic stem cell transplantation (4) 4
hepatocellular-carcinoma (4) 4
hla antigens - immunology (4) 4
in-vitro (4) 4
kinases (4) 4
ovarian cancer (4) 4
receptors, antigen, t-cell - genetics (4) 4
severe combined immunodeficiency (4) 4
t-lymphocytes - immunology (4) 4
transplantation, homologous (4) 4
xenograft model antitumor assays (4) 4
analysis (3) 3
antigen (3) 3
biochemistry & molecular biology (3) 3
bone neoplasms - pathology (3) 3
breast cancer (3) 3
breast-cancer (3) 3
cancer stem cells (3) 3
cancer therapies (3) 3
car (3) 3
cell lines (3) 3
cell proliferation (3) 3
chimeric-antigen-receptor (3) 3
clinical trials (3) 3
cytokine-induced killer cells (3) 3
deoxyribonucleic acid--dna (3) 3
development and progression (3) 3
dna damage (3) 3
drug resistance (3) 3
ewing sarcoma (3) 3
extracellular matrix (3) 3
follow-up (3) 3
gene therapy (3) 3
genetics & heredity (3) 3
graft vs host disease - prevention & control (3) 3
graft vs tumor effect - immunology (3) 3
health aspects (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Cancer, ISSN 1837-9664, 2011, Volume 2, Issue 1, pp. 363 - 368
Cytokine-induced killer (CIK) cells are a heterogeneous subset of ex-vivo expanded T lymphocytes which present a mixed T-NK phenotype and are endowed with a... 
CIK cells | Adoptive immunotherapy | Solid tumors | ONCOLOGY | adoptive immunotherapy | solid tumors
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 01/2015, Volume 15, Issue 12, pp. 1667 - 1670
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 98 - 107
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 12/2015, Volume 15, Issue 12, pp. 1667 - 1670
Journal Article
International Immunology, ISSN 0953-8178, 7/2008, Volume 20, Issue 7, pp. 841 - 848
Journal Article
Journal of Cancer, 2011, Volume 2, p. 363
Cytokine-induced killer (CIK) cells are a heterogeneous subset of ex-vivo expanded T lymphocytes which present a mixed T-NK phenotype and are endowed with a... 
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 1015 - 1015
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2017, Volume 23, Issue 9, pp. 2277 - 2288
Purpose: The MHC-unrestricted activity of cytokine-induced killer (CIK) cells against chemo-surviving melanoma cancer stem cells (mCSC) was explored, as CSCs... 
METASTATIC MELANOMA | ONCOLOGY | LENTIVIRUS VECTOR | IN-VIVO | THERAPY RESISTANCE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | HLA BARRIERS | CIK CELLS | ANTITUMOR-ACTIVITY | CD8(+) T-CELLS | Nitrosourea Compounds - administration & dosage | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Neoplastic Stem Cells - immunology | Lentivirus - genetics | Immunotherapy, Adoptive - methods | Carcinogenesis - immunology | Carcinogenesis - genetics | Neoplasm Recurrence, Local | Drug Resistance, Neoplasm - immunology | Melanoma - pathology | Neoplastic Stem Cells - transplantation | Cytokine-Induced Killer Cells - immunology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cytokine-Induced Killer Cells - transplantation | Cell Line, Tumor | Mice | Organophosphorus Compounds - administration & dosage | Melanoma - therapy | Cytotoxicity, Immunologic | Autografts | Animal models | Cytokines | Oct-4 protein | Immunodeficiency | Melanoma | Chemoresistance | Stem cell transplantation | Gene expression | Anticancer properties | Infusion | Design engineering | Killer cells | Chemotherapy | Dilution | Major histocompatibility complex | Allografts | Experimental design | Immunotherapy | Stem cells | Lysis | Xenografts | Antitumor activity | Cancer | Index Medicus
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 06/2019, Volume 15, Issue 17, pp. 1975 - 1987
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 78, pp. 122 - 132
Journal Article
Molecular Cancer, ISSN 1476-4598, 04/2017, Volume 16, Issue 1, pp. 86 - 86
Background: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an... 
PARP1 inhibitors | DNA-damaging agents | Bone and soft tissue sarcomas | Predictive biomarkers | Olaparib | Trabectedin | Drug synergism | POLY(ADP-RIBOSE) POLYMERASE | DNA-DAMAGE RESPONSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | OLAPARIB MAINTENANCE THERAPY | EWING SARCOMA | BREAST-CANCER | ONCOLOGY | ADP-RIBOSE POLYMERASE | HOMOLOGOUS RECOMBINATION | VELIPARIB ABT-888 | REFRACTORY SOLID TUMORS | PHASE-I | DNA Damage - drug effects | Piperazines - administration & dosage | Phthalazines - administration & dosage | Apoptosis - drug effects | Humans | Tetrahydroisoquinolines - administration & dosage | Sarcoma - drug therapy | Sarcoma - pathology | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Comparative Genomic Hybridization | Dioxoles - administration & dosage | Cell Line, Tumor | Biomarkers, Tumor - genetics | Mice | Gene Expression Regulation, Neoplastic - drug effects | Sarcoma - genetics | Poly (ADP-Ribose) Polymerase-1 - genetics | Drugs | Biotechnology | Animal models | Profiling | DNA damage | Lung cancer | Hybridization | Kinases | DNA repair | Synergism | Alkylation | Anticancer properties | Biomedical materials | Pathways | Osteosarcoma | Rodents | Xenografts | Cell cycle | Biocompatibility | Bioindicators | Damage | Deoxyribonucleic acid--DNA | Enzymes | Sarcoma | Tumor cells | Breast cancer | Gene expression | Polymerase chain reaction | Poly(ADP-ribose) Polymerase 1 | Chemotherapy | Inhibitors | Cell death | Cell lines | Biomarkers | Antitumor activity | In vitro methods and tests | Apoptosis | Index Medicus
Journal Article
Molecular Medicine, ISSN 1076-1551, 01/2017, Volume 23, Issue 1, pp. 235 - 246
Abstract Adoptive immunotherapy with cytokine induced killer (CIK) cells has shown antitumor activity against several kinds of cancer in preclinical models and... 
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 3394 - 3394
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 3591 - 3591
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 02/2017, Volume 9, Issue 2, pp. 219 - 237
The development of resistance remains a major obstacle to long‐term disease control in cancer patients treated with targeted therapies. In BRAF‐mutant mouse... 
Drugs | Phenotypes | Animal models | Transcription | Melanoma | Metastasis | Kinases | Macrophages | Disease control | Metastases | Angiogenesis | Fibroblasts | Hypoxia | Antitumor activity | Extracellular matrix | Software | Mutation | Vascular endothelial growth factor | Colonization | Cancer | Tumors | Apoptosis
Journal Article
Journal Article